Fig. 2From: Efficacy and safety of the biosimilar denosumab candidate (Arylia) compared to the reference product (Prolia®) in postmenopausal osteoporosis: a phase III, randomized, two-armed, double-blind, parallel, active-controlled, and noninferiority clinical trialMean percentage change in BMD of the lumbar spine (L1–L4) (a), total hip (b), and femoral neck (c). Error bars show standard error. The plot is based on the PP setBack to article page